Maze Therapeutics (MAZE) is down -33.2%, or -$16.28 to $32.72.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAZE:
- Leerink remains bullish on Maze, says Vertex comparison ‘apples to oranges’
- Maze Therapeutics price target raised to $110 from $60 at H.C. Wainwright
- Maze Therapeutics reports Q4 EPS (65c), consensus (78c)
- Maze Therapeutics up 15% at $56.43 after Q4 results and MZE829 trial data
- Maze Therapeutics announces positive topline data from Phase 2 HORIZON Trial